Using Apoptosis Inhibitor of Macrophage/CD5L to Forecast Mortality in Critically Ill Sepsis Patients

This study evaluated the usefulness of apoptosis inhibitor of macrophage (AIM)/CD5L as a biomarker to predict morbidity and mortality in critically ill patients with sepsis. A total of 150 adults with sepsis were included. All patients had serum AIM levels measured upon admission to the intensive care unit (ICU), which was compared to survival status and organ dysfunction. A validation cohort of 60 sepsis patients from a different center was also included. The accuracy of AIM in predicting outcomes was also tested in a cohort of 51 pediatric patients with sepsis. Compared to ICU and healthy controls, adult sepsis patients had significantly higher serum AIM levels upon admission. There was a significant association between higher admission serum AIM levels and higher Sequential (sepsis-related) Organ Failure Assessment (SOFA) scores. The area under the receiver operating characteristic curve (AUC) for admission-day AIM level with 28-day mortality was 0.86—higher than AUCs for SOFA (0.77), procalcitonin (0.73), lactate (0.67), IL-27 (0.65), and C-reactive protein (0.55). Sepsis patients with AIM levels > 543.66 ng/mL at admission had a much higher 28-day mortality risk compared to patients whose admission AIM levels were ≤ 543.66 ng/mL. The validation cohort confirmed the correlation between admission AIM levels and 28-day mortality. In the pediatric cohort, the AUC for AIM level association with 28-day mortality was 0.82. Read more